
Stereotactic Body Radiation Therapy in Pancreas Adenocarcinoma Demonstrates Minimal Acute and Late Toxicity

Linda (Yilin) Cao BS¹, Linda Chen MD¹, Amol Narang MD¹, Zachary Guss MD MSc¹, Joseph Moore PhD¹, Scott Robertson PhD¹, Lauren Rosati BS¹, Zhi Cheng MD¹, Omar Mian MD PhD¹, Amy Hacker-Prietz PA-C¹, Todd McNutt PhD¹, Joseph Herman MD MSc^{1,3}

¹Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD ²Corresponding Author



MEDICINE

RADIATION ONCOLOGY & MOLECULAR RADIATION SCIENCES

Grade

Grade 5

Purpose/Objectives	Results				
 Stereotactic body radiation therapy (SBRT) has been increasingly utilized to improve local 	Table 1: Baseline Characteristics Characteristic N (%)	Table 2a: Rates of Acute Toxicity Unlikely SBRT Attributable Potentially SBRT Attributable Total			

Characteristic	N (%)	Acute Toxicity	
Median age at treatment (range), yrs	66 (36-90) 174 (54)	n=321	

 Initial reports of single-fraction PCA SBRT described significant treatment-related toxicity, which is now minimized with treatment modification such as fractionation and active breathing control (ABC)

control in pancreatic cancer (PCA)

 We evaluated institutional rates of acute and late toxicity in PCA SBRT and aimed to identify potential modifiable treatment factors

Methods

- PCA patients (n=321) treated with 5-fraction SBRT from 2010-2016 were retrospectively analyzed
- Acute and late gastrointestinal adverse events
- iviale (70) 174 (04 ECOG performance status (%) 119 (37) ECOG 0 ECOG 1 179 (56 ECOG 2 23 (7) Stage of disease (%) Locally advanced 82 (58 Borderline resectable 187 (26 Other 52 (16) Setting of SBRT (%) 273 (85 Neoadjuvant/upfront 16 (5 Adjuvant 29 (9 Salvage Location of tumor (%) 201 (67) Head Body/tail 88 (33 ≥4 months induction chemotherapy (%) 157 (49) Surgical resection (%) Volumetric-modulated arc therapy (%) 47 (15 Active breathing control (%) 260 (81 Dose prescription (%) 33Gy in 5 fractions 213 (66) Other dose in 5 fractions 108 (34)

4)	n=321	<mark>(</mark> %)	(%)	<mark>(%)</mark>	(%)	(%)	(%)	≥3 (%)
7)	Dehydration	-	-	-	-	-	-	-
6)	Diarrhea	-	-	-	1 (0.3)	-	-	1 (0.3)
(7)	Dyspepsia	-	-	-	-	-	-	-
	Fatigue	-	-	-	1 (0.3)	-	-	1 (0.3)
8)	Nausea	-	-	-	-	-	-	-
6)	Weight Loss	-	-	-	-	-	-	-
6)	Vomiting	-	-	-	-	-	-	-
	Abdominal Pain	-	-	-	5 (1.0)	-	-	5 (1.6)
5)	Ulcer	-	-	-	1 (0.3)	-	-	1 (0.3)
(5)	GI Bleed	1 (0.3)	-	-	2 (0.6)	-	2 (0.6)	5 (1.6)
(9)	Gastritis	1 (0.3)	-	-	3 (0.9)	-	-	4 (1.2)
	Fistula	-	-	-	-	-	-	-
7)	Sepsis	1 (0.3)	-	-	-	-	-	1 (0.3)
3)	Bowel Obstruction	4 (1.2)	1 (0.3)	1 (0.3)	3 (0.3)	-	-	9 (2.8)
	Biliary Obstruction	1 (0.3)	-	1 (0.3)	1 (0.3)	-	-	3 (1.0)
9)	Abscess	1 (0.3)	-	-	-	-	-	1 (0.3)
5)	Enteritis	1 (0.3)	-	-	-	-	-	1 (0.3)
1)	Perforation	1 (0.3)	1 (0.3)	-	-	-	-	2 (0.6)
	Esophagitis	-	-	-	-	-	-	-
6)	Other	-	-	2 (0.6)	-	-	-	2 (0.6)
4								

Grade 3

Table 3: Predictors of Potentially SBRT-Attributable Grade ≥3 AEs


 Table 2b: Rates of Late Toxicity

(AE), defined respectively as occurring within and beyond 90 days of treatment, were assessed using the CTCAE v3.0

- Grade ≥3 adverse events were categorized as either unlikely or potentially attributable to SBRT by group consensus of 3 physicians
- Multivariate logistic regression was used to assess toxicity outcomes with respect to performance status, ABC use, surgical resection, induction chemotherapy duration, and dose to sum of proximal organs-at-risk (duodenum, stomach, and bowel)

Variable	p-value	OR: 95% CI	Late To
ECOG < 2	>0.05		n=2
Surgical Resection	>0.05		
ABC	>0.05		Ulcer
Chemo > 4 months	>0.05		GI Bleed
Dosimetric Variable			Gastritis
(sum of proximal OAR)			Fistula
V15 ^a	0.031	1.010: 1.001–1.020	Sepsis
V15 < 75cc [♭]	0.043	0.249: 0.065–0.954	Bowel Ob
V20 ^a	0.023	1.022: 1.003–1.041	Biliary Ob
V20 < 45cc ^b	0.012	0.167: 0.041–0.676	Abscess
V25 ^a	0.027	1.033: 1.004–1.064	Enteritis
V25 < 9cc ^b	0.129	0.402: 0.124–1.300	Perforatio
V30 ^a	0.036	1.045: 1.003–1.089	Esophagit
V30 < 1.5cc ^b	0.134	0.438: 0.149–1.290	Pain
V33 ^a	0.060	1.051: 0.998–1.107	Other
V33 < 1.1cc ^b	0.035	0.306: 0.101–0.922	
	i	· · · · · · · · · · · · · · · · · · ·	

^a continuous variable ^b categorical variable








Figure 1: Sample pancreas SBRT treatment plan

Our institution's PCA SBRT treatment protocol is well tolerated. Our experience may provide insight into dosimetric constraints to proximal organs-at-risk associated with

Grade \geq 3 toxicity.